@entity2682 for relief of @entity508 associated with XXXX .

@entity1 @entity1246 @entity2682 @entity508 @entity15
The use of a recently released anticonvulsant, @entity2682 , in the treatment of @entity508 in two @entity1 with @entity15 is reported. @entity2682 was chosen because of its @entity1246 -ergic effect and because previously reported studies have shown that it is well tolerated compared with other @entity1246 -mimetic medication. Satisfactory release of @entity508 with significant improvement of functional outcome was noted in both cases. Both @entity1 were first treated with @entity2682 for one month at 300 mg per day and then, with no reported side-effects, at 400 mg per day. Before treatment, @entity508 (graded with modified Ashworth Scale) in one @entity1 was 3 for left lower and 2 for right lower limbs, and Expanded Disability Status Scale (EDSS) was 7; ambulation was limited to a few steps with a standard walker. After two weeks of treatment, @entity508 was 2 and 1 for the left and right lower limbs, respectively. At three-month intervals, @entity508 was +1 for left and 1 for right lower limbs, and EDSS was 6; the @entity1 could ambulate 75 to 100 m with a standard walker. In the second @entity1 , @entity508 before treatment was 2 for both lower and left upper limbs. EDSS was 5.5, and ambulation was confined to 100 m with a cane. Spasticity improved to +1 in lower and 1 in left upper limbs after two weeks and to 1 and normal after three months. At three months, EDSS was 3 and the @entity1 could ambulate for long distances without an assistive device. We suggest that @entity2682 can be used effectively to decrease @entity508 without significant side effects in @entity1 with @entity15 .
